BioMarin Pharmaceuticals BMRN Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's accounts receivable?
- BioMarin Pharmaceuticals (BMRN) reported accounts receivable of $903.91M in Q1 2026.
- How has BioMarin Pharmaceuticals's accounts receivable changed year-over-year?
- BioMarin Pharmaceuticals's accounts receivable increased by 22.3% year-over-year, from $739.18M to $903.91M.
- What is the long-term trend for BioMarin Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accounts receivable has grown at a 15.2% compound annual growth rate (CAGR), from $448.35M to $908.21M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products already delivered.
- How do you interpret accounts receivable?
- A rising ratio relative to revenue may indicate collection difficulties or deteriorating customer credit quality, while a stable ratio suggests efficient billing processes.
- How does accounts receivable compare across companies?
- Standard across all commercial-stage pharmaceutical companies, with variations based on payer mix and regional reimbursement cycles.